Literature DB >> 729608

Pharmacokinetics of sulfadiazine and trimethoprim in man.

F Andreasen, L Elsborg, S Husted, O Thomsen.   

Abstract

Sulfadiazine (SDZ) 800 mg and trimethoprim (TMP) 160 mg were given orally to 10 normal subjects and the concentration of SDZ and TMP in serum and urine was followed for 24 h. Both drugs showed a significant negative correlation between individual "peak" concentrations in serum and the body weight of the subject. Twelve hours after dosing the serum concentration was 12 to 25 microgram/ml for SDZ and 0.3 to 1.1 microgram/ml for TMP. Individual concentration ratios between SDZ and TMP in serum were 4.8 (1 h)--145 (24 h), and in the urine the ratio was close to 6 throughout the 24 h collection period. The range of urinary concentrations was from 65 to 400 microgram/ml for SDZ and from 13.8 to 93.4 microgram/ml for TMP. The fraction (formula: see text) was 21% during the 0--8 h period, 33% during the 8--15 h period and 41% during the 15--24 period. The average "t1/2" was 15.2 +/- 7.4 h for SDZ and 7.4 +/- 1.9 h for TMP. Individual subjects showed a significant correlation between the serum clearance of TMP and SDZ (p less than 0.01) and also between the renal clearance of the two drugs (p less than 0.05). The serum clearance was significantly correlated with the renal clearance for TMP but not for SDZ. For SDZ Vd was significantly negatively correlated with the elimination constant; for TMP no such correlation was found. The serum clearance of SDZ was significantly correlated with the percentage of SDZ which was excreted as the (presumably) acetylated compound. The renal clearance of SDZ was independent of the serum concentration of SDZ. There was a highly significant negative correlation between the renal clearance and serum concentration of TMP, as well as for "acetylated SDZ". The renal clearance of "acetylated SDZ" averaged more than six times that of unconjugated SDZ. With increased urine flow the renal clearances of TMP and SDZ were significantly increased.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 729608     DOI: 10.1007/bf00560259

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Kinetics of a sulfadiazine-trimethoprim combination.

Authors:  T Bergan; H Vik-Mo; U Anstad
Journal:  Clin Pharmacol Ther       Date:  1977-08       Impact factor: 6.875

2.  Pharmacokinetic studies with trimethoprim and different doses of sulfadiazine in healthy human subjects.

Authors:  P Männistö; J Tuomisto; N E Saris; T Lehtinen
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

Review 3.  Trimethoprim-sulfamethoxazole: in vitro microbiological aspects.

Authors:  S R Bushby
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

4.  Quantification of the antibacterial action of trimethoprim alone and in combination with sulfonamides by bacterial growth kinetics.

Authors:  J K Seydel; E Wempe; G H Miller; L Miller
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

5.  Kidney transport in man of sulfamethoxazole and trimethoprim.

Authors:  T Bergan; E K Brodwall
Journal:  Chemotherapy       Date:  1972       Impact factor: 2.544

6.  Absorption and urinary execretion of trimethoprim, sulfamethoxazole, and trimethoprim-sulfamethoxazole: results with single doses in normal young adults and preliminary observations during therapy with trimethoprim-sulfamethoxazole.

Authors:  M C Bach; O Gold; M Finland
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

7.  Metabolism of trimethoprim in man and measurement of a new metabolite: a new fluorescence assay.

Authors:  C W Sigel; M E Grace; C A Nichol
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

8.  The renal handling of trimethoprim and sulphamethoxazole in man.

Authors:  P Sharpstone
Journal:  Postgrad Med J       Date:  1969-11       Impact factor: 2.401

9.  Susceptibility of recently isolated pathogenic bacteria to trimethoprim and sulfamethoxazole separately and combined.

Authors:  M C Bach; M Finland; O Gold; C Wilcox
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

10.  Quantitative determination of the bacteriostatically active fraction of sulfonamides and the sum of their inactive metabolites in the body fluids.

Authors:  J Rieder
Journal:  Chemotherapy       Date:  1972       Impact factor: 2.544

View more
  3 in total

Review 1.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

2.  In vitro effects of folate inhibitors on Toxoplasma gondii.

Authors:  F Derouin; C Chastang
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

3.  Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine.

Authors:  E Schoondermark-van de Ven; J Galama; T Vree; W Camps; I Baars; T Eskes; J Meuwissen; W Melchers
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.